Skip to main content

TransMedics Group, Inc.

For the period ended Jun 30, 2026. Filed Aug 4, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 4, 2026

TMDX$90.95-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Revenue:
Net product revenue$111,158$96,100$219,130$184,334
Service revenue78,79061,270144,751116,573
Total revenue189,948157,370363,881300,907
Cost of revenue:
Cost of net product revenue25,56619,42149,87435,733
Cost of service revenue51,18441,36099,64880,357
Total cost of revenue76,75060,781149,522116,090
Gross profit113,19896,589214,359184,817
Operating expenses:
Research, development and clinical trials31,63215,93456,51133,094
Selling, general and administrative57,83044,088120,81587,713
Total operating expenses89,46260,022177,326120,807
Income from operations23,73636,56737,03364,010
Other income (expense):
Interest expense(7,225)(3,476)(14,395)(6,937)
Interest income and other income (expense), net2,8943,0915,2525,785
Total other expense, net(4,331)(385)(9,143)(1,152)
Income before income taxes19,40536,18227,89062,858
Provision for income taxes(4,723)(1,275)(5,893)(2,269)
Net income$14,682$34,907$21,997$60,589
Net income per share:
Basic$0.42$1.03$0.64$1.79
Diluted$0.41$0.92$0.61$1.62
Weighted average common shares outstanding:
Basic34,579,98033,912,66934,482,63433,817,664
Diluted40,709,22740,558,95336,003,67740,238,501
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.